* todayRCE is tackling the global health problem of...

* today

RCE is tackling the global health problem of antibiotic-resistant superbugs and emerging viral pathogens with its new class of synthetic anti-infectives.In February, RCE announced it had signed a MoU with PT Etana Biotechnologies Indonesia to research, develop, distribute and commercialise a first-in-class therapeutic with broad-spectrum anti-infective capabilities.Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market.RCE said Indonesia was the gateway to the 10 ASEAN member states, covering a population of 670 million people."The global health challenge of antimicrobial resistance is a pressing issue on the world stage," Indonesian Minister of Health Budi Sadikin said when the collaboration was announced.RCE CEO James Graham said the collaboration between RCE and Etana signified the Australian and Indonesian Governments’ shared commitment to advancing public health, fostering innovation, and addressing the global challenge of AMR in the Asia Pacific region."Indonesia welcomes collaborative initiatives and supports efforts to combat antimicrobial resistance, including the development of innovative therapeutics for infectious diseases," he said.RCE is preparing to undertake a registration Phase 3 diabetic foot infection (DFI) clinical trial, intended to start late 2024.RDI said 11% of Indonesian have diabetes, one of the highest prevalences in the world, and making patient populations readily available to focus on significant unmet medical needs, such as the treatment of DFIs."With a total population of 8.5m Diabetes Mellitus patients in Indonesia, the potential of bringing a new treatment solution for diabetic foot infections is much needed," he said.* today